You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

How Effective Is the COVID-19 Vaccine in Young Children?

  • Authors: News Author: Lisa O’Mary; CME Authors: Laurie Barclay, MD, Charles P. Vega, MD
  • CME / ABIM MOC / CE Released: 4/21/2023
  • Valid for credit through: 4/21/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    Physician Assistant - 0.50 AAPA hour(s) of Category I credit

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for pediatricians, infectious disease physicians, internists, nurses, nurse practitioners, family medicine/primary care clinicians, pharmacists, physician assistants, and other members of the healthcare team caring for young children needing vaccination against COVID-19 and their parents.

The goal of this activity is for members of the healthcare team to be better able to describe safety, immunogenicity, and efficacy data from recent trial data for mRNA COVID-19 vaccines in children.

Upon completion of this activity, participants will:

  • Describe safety, immunogenicity, and efficacy data from trial data evaluating the mRNA COVID-19 vaccines in healthy children aged <5 years
  • Identify clinical and public health implications of safety, immunogenicity, and efficacy data from trial data evaluating the mRNA COVID-19 vaccines in healthy children aged <5 years
  • Outline Implications for the Healthcare Team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Lisa O’Mary

    Freelance writer, Medscape

    Disclosures

    Lisa O’Mary has no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Laurie Barclay, MD, has no relevant financial relationships.

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: Boehringer Ingelheim; GlaxoSmithKline; Johnson & Johnson

Editor/Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-23-115-H06-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 4/21/2024. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

How Effective Is the COVID-19 Vaccine in Young Children?

Authors: News Author: Lisa O’Mary; CME Authors: Laurie Barclay, MD, Charles P. Vega, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 4/21/2023

Valid for credit through: 4/21/2024, 11:59 PM EST

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to COVID-19 vaccines are provided in this activity in an effort to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.

Clinical Context

COVID-19 is generally mild in children aged < 5 years, but severe disease, hospitalizations, and multisystem inflammatory syndrome in children (MIS-C) can occur. In a previous study by Anderson and colleagues, they investigated the safety and efficacy of a 2-dose series of the Moderna vaccine (mRNA-1273) for children aged 6 months to 5 years and found the series to have an acceptable safety profile and to elicit immune responses consistent with higher doses given to older children, adolescents, and adults. Their results were published in the November 3, 2022 issue of the New England Journal of Medicine.[1]

BNT162b2 vaccine has US licensure for COVID-19 immunization in persons aged ≥ 12 years and emergency use authorization (EUA) for children aged 5 to 11 years. In children aged 2 to 4 years, a 2-dose primary series failed some criteria for immunobridging success. Emerging evidence suggests that 3 mRNA vaccine doses are needed to enhance immune responses against Omicron. The current study by Muñoz and colleagues therefore investigated a third 3-μg BNT162b2 dose given ≥ 8 weeks after dose 2 in children aged 6 months to 4 years.

Study Synopsis and Perspective

In the current study, the authors show the Pfizer-BioNTech vaccine (BNT162b2) is safe and highly effective against COVID-19 in children as young as 6 months old.

A 3-dose series of the vaccine was 73% effective at preventing symptomatic COVID-19 in children aged 6 months to 4 years old, the researchers found. They also discovered that an examination of reactions and safety results “did not suggest any concerns.”

The study, published in The New England Journal of Medicine, included 1776 children aged 6 months to 2 years and 2750 children aged 2 to 4 years. Researchers randomly assigned children to receive either the 3-shot series of the BNT162b2 vaccine or placebo shots. Participants received the first dose of the vaccine by March 31, 2022, and lived in Brazil, Finland, Poland, Spain, or the United States.[2]

The authors wrote that having safe and effective COVID-19 vaccines for young children is important to protect them from hospitalization or death and because young children play a role in spreading highly transmissible variants of the virus. COVID-19 hospitalizations for children younger than 5 years old peaked at a rate of 14.5 per 100,000 in January 2022, the authors wrote, noting that the Omicron virus variant appeared to affect young children more severely than the previous variant, Delta.

When the researchers evaluated vaccine effectiveness by age group, they found that it prevented symptomatic COVID-19 in 75.8% of children aged 6 months to 2 years and in 71.8% of children aged 2 to 4 years.

Less than 0.5% of participants reported severe reactions to the vaccine. The most common reactions reported were tenderness or pain. Reactions typically appeared within the first couple days after vaccine administration and resolved within 2 days. Participants reported zero cases of inflammation of the heart muscle or its lining.

Uptake of COVID-19 vaccines for young children has been lower than other age groups in the United States. The Centers for Disease Control and Prevention (CDC) said 10% of children younger than 5 years have received at least 1 dose of a COVID-19 vaccine, and 5% have completed a primary vaccine series.[3]

Please see Study Highlights below for a synopsis of recent studies published on the safety and efficacy of the 2 mRNA COVID-19 vaccines that have received EUA from the FDA for children to aged older than 6 months.

Study Highlights: Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)

  • During the dose-finding study, 2 doses of BNT162b2 were given 21 days apart to 16 children aged 6 months to < 2 years (3 μg) and 48 children aged 2 to 4 years (3 or 10 μg).
  • In the phase 2 to 3 trial, researchers randomly assigned participants 2:1 to receive two 3-μg doses of BNT162b2 (1178 children aged 6 months to < 2 years and 1835 children aged 2 to 4 years) or placebo (598 and 915, respectively).
  • From January 2022, when Omicron emerged, a third 3-μg dose (≥ 8 weeks after dose 2) was given, based on preliminary immunogenicity results.
  • Immune responses at 1 month after doses 2 and 3 in children aged 6 months to < 2 years and in children aged 2 to 4 years were immunologically bridged to responses after dose 2 in persons aged 16 to 25 years given 30 μg BNT162b2 in the pivotal trial.
  • Both age groups met immunobridging success criteria for geometric mean ratio and seroresponse at 1 month after dose 3.
  • Local reactions were more frequent within 7 days after BNT162b2 than after placebo; most were mild to moderate; ≤ 0.3% were severe; none were grade 4.
  • The most frequent local reaction was tenderness among children aged 6 months to < 2 years and pain among children aged 2 to 4 years; swelling and redness were less frequent.
  • Median time of onset for all local reactions was 1 to 2 days after injection; most resolved within 1 to 2 days.
  • Incidences of local reactions after dose 3 were generally similar to or lower than those after dose 1 or 2.
  • Low, similar incidences of fever were reported after BNT162b2 (7% among children aged 6 months to < 2 years; 5% among children aged 2 to 4 years) and placebo (6%-7% and 4%-5%, respectively).
  • Among children aged 6 months to < 2 years, systemic events other than fever were more frequent after BNT162b2 than after placebo; among children aged 2 to 4 years, systemic events occurred at generally similar frequencies in both groups.
  • Systemic events were mostly mild to moderate; severe in ≤ 1.1%; none were grade 4.
  • The most frequent systemic event was irritability among children aged 6 months to < 2 years and fatigue among children aged 2 to 4 years.
  • Median onset for most events after BNT162b2 was 2 to 3 days; most resolved within 1 to 2 days.
  • Overall, adverse event (AE) frequencies were similar for BNT162b2 and placebo in both age groups and were higher among the younger group.
  • Few participants withdrew for AEs.
  • There were no deaths, myocarditis or pericarditis, facial weakness, thromboembolism, thrombocytopenia, MIS-C, Kawasaki disease, acute respiratory distress syndrome, meningitis, myelitis or encephalomyelitis, vaccine-related anaphylaxis, demyelination, peripheral neuropathy, or vasculitis.
  • Among children aged 6 months to 4 years, there were 13 COVID-19 cases in the BNT162b2 group and 21 in the placebo group from ≥ 7 days after dose 3 to the data-cutoff date, entirely during the Omicron-dominant phase.
  • Vaccine efficacy was 73.2% (95% CI: 43.8%, 87.6%) overall, 75.8% (95% CI: 9.7%, 94.7%) among children aged 6 months to < 2 years and 71.8% (95% CI: 28.6%, 89.4%) among children aged 2 to 4 years.
  • Omicron BA.2.12.1 and BA.2 caused most COVID-19 cases from 7 days after dose 3.
  • Among children aged 6 months to 4 years, vaccine efficacy was 71.8% (95% CI: 40.5%, 87.1%) against all Omicron variants; 71.1% (95% CI: 9.1%, 91.5%) against BA.2.12.1, 89.2% (95% CI: 45.7%, 98.9%) against BA.2, and 13.3% (95% CI: −5016.9%, 95.5%) against BA.4.
  • The investigators concluded that two 3-μg BNT162b2 doses given 21 days apart followed by a third dose ≥ 8 weeks later was safe, immunogenic, and efficacious in children aged 6 months to 4 years from ≥ 7 days after dose 3, during the Omicron-dominant phase.
  • Immunogenicity data showed robust vaccine-elicited immune responses, including successful immunobridging to young adults from the original adult efficacy study, according to neutralizing titers against the ancestral SARS-CoV-2 strain.
  • Among children aged 2 to 4 years, immunobridging data after dose 2 only partially met success criteria.
  • To achieve high effectiveness against symptomatic and severe COVID-19, including from Omicron BA.1 or BA.2, real-world studies in older populations including adolescents also showed the need for additional vaccine doses beyond the initial 2 doses.
  • A third dose was therefore authorized for persons aged ≥ 5 years, and a 3-dose primary series was evaluated in children aged < 5 years.
  • In an exploratory analysis, three 3-μg BNT162b2 doses induced neutralizing titers against Omicron BA.1, with response patterns generally similar to those in adults aged 18 to 50 years given a third dose (booster) at an interval similar to that used for doses 2 and 3 in young children (~ 3 months).
  • Taken together, the evidence supports vaccination of children aged 6 months to 4 years with three 3-μg primary BNT162b2 doses, leading to recent EUA.
  • The CDC now recommends BNT162b2 or another COVID-19 messenger RNA (mRNA) vaccine.
  • COVID-19 vaccine availability for young children is essential, given their surge in Omicron-related cases and hospitalizations, and the family burden, including childcare–related employment disruption, of COVID-19 in young children.
  • Unpredictability of new variants, including Omicron BA.4 and BA.5 sublineages, requires protection against severe COVID-19 among young children.
  • As masking and other mitigation measures are lifted, vaccinating young children would expand direct protection and add another layer of community protection against symptomatic, severe COVID-19.
  • The observed BNT162b2 safety profile and reactogenicity did not suggest any concerns in young children.
  • Study limitations include insufficient power to assess efficacy against severe disease or specific variants or to detect potential rare AEs, predominantly White participants, and lack of assessment of simultaneous administration of BNT162b2 with other vaccines
  • Follow-up from this trial (for ≥ 1 year after dose 3) and effectiveness and safety data from real-world use should give further information.
  • According to data from older populations, all age groups may need additional doses beyond the primary series to cover waning immunity, with variant-specific formulations to protect against emerging strains.

Study Highlights: Moderna COVID-19 Vaccine (mRNA-1273)

  • The study was divided into 2 age cohorts: 6 to 23 months and 2 to 5 years. Children were recruited from 79 sites in the United States and 8 in Canada.
  • Researchers randomly assigned participants to receive two 25-µg doses of mRNA-1273 or placebo dosed 1 month apart.
  • The main study outcomes were the safety and immunogenicity of mRNA-1273 vs placebo. A serologic response to the vaccine was defined by at least a 4-fold increase in neutralizing antibody concentration against SARS-CoV-2. Researchers compared the serologic response of mRNA-1273 in children with that of a previous cohort of young adults aged between 18 and 25 years.
  • The secondary study outcome was the incidence of infection with SARS-CoV-2. The diagnosis of COVID-19 required at least one systemic or respiratory symptom along with a positive reverse-transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2.
  • Between April 2021 and June 2021, investigators randomly assigned 3040 children between the ages of 2 and 5 years to receive mRNA-1273, along with 1762 children between the ages of 6 and 23 months. 1008 and 593 children in each respective age group received placebo.
  • The median age of participants in the 2- to 5 year-old age group was 3 years. 76.5% of participants in this group were White. The median age of participants in the 6- to 23 month-old age group was 16 months, and 78.9% of participants in this group were White. The cohort overall was equally divided among girls and boys.
  • Adherence to the study injections exceeded 90%. The median duration of follow-up after the second injection in the 2- to 5-year and 6- to 23-month groups were 71 and 68 days, respectively.
  • AEs were more common in the mRNA-1273 groups vs placebo, but most of these events were mild and transient. Among children between the ages of 6 and 23 months, localized reactions occurred in 44% and 54% of participants after the first and second injections of mRNA-1273, respectively. The respective rates of localized reactions in the placebo group were 33% and 30%.
  • Among children aged between 6 and 23 months, systemic reactions occurred in 76% and 74% of participants after the first and second injections of mRNA-1273, respectively. The respective rates of systemic reactions in the placebo group were 72% and 67%.
  • There was a larger gap in the rate of AEs in comparing placebo and mRNA-1273 among older children, with the second dose particularly associated with a higher rate of local (70% to 75%) and systemic (59% to 68%) reactions.
  • 8 serious AEs occurred in the mRNA-1273 group aged 6 to 23 months compared with 0 in the placebo group. There were no serious AEs in the 2- to 5- year-old cohort.
  • No cases of death, myocarditis, pericarditis, or MIS-C were recorded.
  • At day 57, neutralizing antibody geometric mean concentrations against SARS-CoV-2 were 1410 (95% CI: 1272, 1563) among 2- to 5-year-olds and 1781 (95% CI: 1616, 1962) among 6- to 23-month-olds. These results were similar compared with the immunologic response among young adults and met criteria for noninferiority.
  • mRNA-1273 demonstrated robust immunogenicity for ancestral variants of SARS-CoV-2 along with the omicron variant.
  • Among 2- to 5-year-old children, the incidence rates of COVID-19 were 4.6% and 7.1% in the mRNA-1273 and placebo groups, respectively. Vaccine efficacy was 36.8% after the second injection.
  • Among 6- to 23 month-old children, the incidence rates of COVID-19 were 3.4% and 6.6% in the mRNA-1273 and placebo groups, respectively. Vaccine efficacy was 50.6%.
  • mRNA-1273 also demonstrated vaccine efficacy against asymptomatic infection.

Clinical Implications

  • Two 3-μg BNT162b2 doses given 21 days apart followed by a third dose ≥ 8 weeks later was safe, immunogenic, and efficacious in children aged 6 months to 4 years.
  • New evidence supports vaccination of children aged 6 months to 4 years with three 3-μg primary BNT162b2 doses, leading to recent EUA, or with another COVID-19 mRNA vaccine.
  • Implications for the Healthcare Team: Members of the healthcare team should educate patients and caregivers that additional doses beyond the primary series may be needed to cover waning immunity, with variant-specific formulations to protect against emerging strains.

 

Earn Credit

  • Print